The use of anti-inflammatory or anti-oxidant treatments in the Ts65Dn model, including treatment with minocycline, vitamin E, resolvin E, granulocyte-macrophage colony-stimulating factor or anti-IL-17, rescues some of these neuroinflammatory phenotypes, neurodegeneration and cognition (Hunter et al., 2004a; Lockrow et al., 2009; Rueda et al., 2018; Hamlett et al., 2020a; Ahmed et al., 2022), showing the important role that neuroinflammation may have in AD-DS phenotypes. The gene discussed is IL17A; the disease is Dravet syndrome.